CDT Completes Global AZD5904 Patent Coverage, Targets $4.4B Male Infertility Market
CDT•CDT secured Canadian patent for AZD5904 in male infertility, completing approval across all major pharmaceutical markets. The drug targets a US$4.4 billion annual market and leverages AstraZeneca's clinical safety data as CDT advances licensing and strategic partnership discussions.
1. Patent Approval in Canada
CDT received Canadian patent approval for AZD5904 in male infertility, fulfilling patent coverage across all principal pharmaceutical markets following prior grants in the US, EU, Japan, and other territories.
2. Market Potential
The global male infertility market lacks approved therapies and is valued at about US$4.4 billion annually, presenting significant commercial opportunity for an AZD5904-based treatment addressing unmet medical need.
3. Strategic Partnership Outlook
Leveraging AstraZeneca's existing clinical safety data and the strengthened IP position, CDT is in discussions for licensing and strategic partnerships to advance AZD5904 toward clinical development and eventual commercialization.
